10,715 Shares in Bruker Corporation $BRKR Bought by State of Wyoming

State of Wyoming bought a new stake in shares of Bruker Corporation (NASDAQ:BRKR) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 10,715 shares of the medical research company’s stock, valued at approximately $694,000.

Other institutional investors have also bought and sold shares of the company. Essential Partners LLC purchased a new stake in Bruker in the 1st quarter valued at $36,000. Global Retirement Partners LLC bought a new position in Bruker during the 2nd quarter valued at $38,000. EverSource Wealth Advisors LLC boosted its holdings in Bruker by 532.9% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,500 shares of the medical research company’s stock worth $54,000 after acquiring an additional 1,263 shares during the last quarter. Root Financial Partners LLC purchased a new position in Bruker during the 3rd quarter worth $57,000. Finally, FNY Investment Advisers LLC purchased a new position in Bruker during the 2nd quarter worth $60,000. Institutional investors own 79.52% of the company’s stock.

Bruker Trading Down 8.0%

NASDAQ BRKR opened at $57.07 on Friday. The business’s fifty day moving average is $58.90 and its 200-day moving average is $50.35. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.85 and a quick ratio of 0.92. The stock has a market capitalization of $8.70 billion, a price-to-earnings ratio of -81.53, a PEG ratio of 1.75 and a beta of 1.22. Bruker Corporation has a one year low of $32.37 and a one year high of $66.98.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.11. The company had revenue of $838.50 million during the quarter, compared to analyst estimates of $853.57 million. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.32 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Equities research analysts predict that Bruker Corporation will post 2.12 EPS for the current year.

Bruker Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Shareholders of record on Monday, September 21st were paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date was Monday, September 21st. Bruker’s payout ratio is presently -28.57%.

Wall Street Analyst Weigh In

Several analysts have recently commented on BRKR shares. Guggenheim increased their target price on shares of Bruker from $70.00 to $72.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Weiss Ratings reissued a “sell (d+)” rating on shares of Bruker in a research report on Monday, August 31st. Stifel Nicolaus set a $50.00 price target on shares of Bruker in a report on Wednesday, August 5th. Citigroup reduced their price objective on shares of Bruker from $60.00 to $53.00 and set a “hold” rating for the company in a research report on Wednesday, August 5th. Finally, JPMorgan Chase & Co. downgraded shares of Bruker from an “overweight” rating to a “neutral” rating and set a $60.00 price objective for the company. in a research report on Wednesday, October 14th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $59.43.

Insiders Place Their Bets

In other news, VP Mark Munch sold 2,000 shares of the stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total transaction of $105,740.00. Following the completion of the transaction, the vice president directly owned 134,806 shares of the company’s stock, valued at $7,127,193.22. This represents a 1.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 27.20% of the stock is currently owned by insiders.

Bruker Profile

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, molecules and biological processes. Its technologies support research, discovery and quality control in fields including life sciences, pharmaceutical development, chemical analysis, materials science, environmental testing and clinical research.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, infrared and Raman spectroscopy instruments, X-ray analysis equipment, microscopy and nanoanalysis systems, and preclinical imaging technologies.